Detail of "120287-85-6"

Reference

Analogs of luteinizing hormone-releasing hormone in benign prostatic hyperplasia and advanced renal cell carcinoma

Analogs of luteinizing hormone-releasing hormone in benign prostatic hyperplasia and advanced renal cell carcinoma. Comaru-Schally, A. M. (Endocrine, Polypeptide and Cancer Institute, VA Medical Center, New Orleans, LA, USA). Peptides and Non-Peptides of Oncologic and Neuroendocrine Relevance, 21-28. Edited by: Mueller, Eugenio E. Springer-Verlag Italia: Milan, Italy. ISBN: 88-470-0295-8(English) 2003. CODEN: 69EWP2. DOCUMENT TYPE: Conference CA Section: 2 (Mammalian Hormones) Benign prostatic hyperplasia (BPH) is a significant health problem all over the world. This condition will affect most men should they live long enough and can lead to serious complications, such as acute or chronic urinary retention, renal insufficiency, urinary tract infection and sexual dysfunction. Symptomatic BPH causes morbidity and can lower the quality of life (QoL). This study investigated whether short-term administration of the LHRH antagonist cetrorelix could provide a new treatment for men with BPH.Except for chemicals metioned above, 120287-85-6 and 9034-40-6 are also used. .

Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis

All Rights Reserved. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Kolibianakis, E. M.; Collins, J.; Tarlatzis, B. C. 120287-85-6 and 9002-61-3 are cas registry numbers. These chemicals are also mentioned in this article.; Devroey, P.; Diedrich, K.; Griesinger, G. (Unit for Human Reproduction, 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece). Human Reproduction Update, 12(6), 651-671 (English) 2006 Oxford University Press. CODEN: HRUPF8. ISSN: 1355-4786. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) This systematic review and meta-anal. aimed to answer the following clin. question: among patients treated for IVF with gonadotrophins and GnRH analogs, is the probability of live birth per randomized patient dependent on the type of analog used Eligible studies were randomized controlled trials (RCTs), published as a full manuscript in a peer-reviewed journal, that contained sufficient information to allow ascertainment of whether randomization was true and whether equality was present between the groups compared. A literature search identified 22 RCTs comparing GnRH antagonists and GnRH agonists that involved 3176 subjects. Where live birth was not reported in a study that fulfilled the inclusion criteria, an effort was made to contact the corresponding authors to retrieve the missing information. If this was not possible, the reported outcome measure, clin. pregnancy or ongoing pregnancy was converted to live birth in 12 studies using published data (Arce et al., 2005). No significant difference was present in the probability of live birth between the two GnRH analogs [odds ratio (OR), 0.86; 95% confidence intervals (CI), 0.72 to 1.02]. This result remains stable in subgroup anal. that ordered the studies by type of population studied, gonadotrophin type used for stimulation, type of agonist protocol used, type of agonist used, type of antagonist protocol used, type of antagonist used, presence of allocation concealment, presence of co-intervention and the way the information on live birth was retrieved. In conclusion, the probability of live birth after ovarian stimulation for IVF does not depend on the type of analog used for pituitary suppression. .